Full Text View
Tabular View
No Study Results Posted
Related Studies
Iressa Study in Patients With Salivary Gland Cancer
This study is ongoing, but not recruiting participants.

First Received on July 26, 2007.   Last Updated on September 22, 2011   History of Changes
Sponsor: M.D. Anderson Cancer Center
Collaborator: AstraZeneca
Information provided by (Responsible Party): M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT00509002
  Purpose

Primary Objective:

1. To determine the response rate of in patients with advanced, recurrent, or metastatic salivary gland cancer who are not candidate for curative surgery or radiotherapy.

Secondary Objectives:

  1. To determine progression-free survival and overall survival.
  2. To determine disease control rate and duration.
  3. To determine time to disease progression.
  4. To further characterize the safety profile of 250 mg daily dose of ZD1839.

Exploratory Objectives:

  1. To demonstrate the effectiveness of ZD1839 as an inhibitor of epithelial growth factor (EGFR) phosphorylation, MAP kinase activation, and vascular endothelial growth factor (VEGF) secretion in salivary gland cancer.
  2. To estimate the correlation of HER2/neu expression and the probability of tumor response.

Condition Intervention Phase
Salivary Gland Cancer
 Drug: ZD1839 (Iressa)
 Phase II

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of ZD1839 (Iressa®), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor in Patients With Advanced, Recurrent or Metastatic Salivary Gland Cancer (IRUSIRES0198)

Resource links provided by NLM:

MedlinePlus related topics: Cancer
Drug Information available for: ZD1839
U.S. FDA Resources

Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:
  • Response Rate in Patients [ Time Frame: Every 4 weeks until progressive disease, unacceptable toxicity or patient withdrawal ] [ Designated as safety issue: No ]

Estimated Enrollment: 80
Study Start Date: May 2004
Estimated Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ZD1839 (Iressa)
250 mg daily
 Drug: ZD1839 (Iressa)
250 mg by mouth once a day, every day, at about same time in morning.
Other Name: gefitinib

Detailed Description:

Epidermal growth factor receptor (EGFR) may be involved in certain types of cancer, including squamous cell carcinoma of the skin. When EGFR is stimulated, a series of chemical reactions starts that results in a tumor being "told" to grow. ZD1839 (Iressa® or Gefitinib) tries to stop these reactions by blocking EGFR. This may stop tumors from growing.

Before you can start treatment on the study, you will have what are called "screening tests". These tests will help the doctor decide if you are eligible to take part in the study. You will have a physical exam, and a CT scan to check on the size and location of the tumor. If the diagnosis has not yet been confirmed, a tumor sample (biopsy) may need to be collected. During this biopsy, a tumor sample and a sample of normal skin will be taken with a large needle. Women who are able to have children must have a negative blood or urine pregnancy test.

If you are eligible to take part in this study, you will take gefitinib treatment by mouth once a day, every day, at about the same time in the morning. It can be taken with or without food. If you forget to take a dose, the last missed dose should be taken as soon as you remember, as long as it is at least 12 hours before the next dose is due to be taken.

Every four weeks during treatment, you will have a physical exam and blood (around 3-4 teaspoons) will be collected for routine tests. If you have skin lesions, the lesions will be measured and photographed for research purposes. You cannot be identified from the pictures. You will also be asked about any side effects you may be experiencing. If your doctor feels it is necessary, you may have more frequent check-ups.

Every eight weeks during treatment, you will have imaging tests. The imaging tests include, a chest x-ray and a CT scan or MRI of the head and neck area. You may also have CT scans of other areas of the body. These tests are being done to check on the status of the disease.

You will continue to take gefitinib as long as the disease is responding to treatment. If at any time during the study the disease becomes worse or you experience any intolerable side effects, you will be taken off the study and your doctor will discuss other treatment options with you.

Sometimes, new information becomes available that may influence your decision to continue in the study. The following new information is available:

Results from two large studies showed that there was no benefit from adding gefitinib to chemotherapy with platinum and one other chemotherapy drug when given as the first treatment for non-small cell lung cancer (NSCLC). Therefore, gefitinib is not approved for use in combination with chemotherapy in the treatment of NSCLC.

This is an investigational study. The FDA has authorized gefitinib for use in cancer research. Up to 80 patients will take part in this study. All will be enrolled at M. D. Anderson.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically or cytologically confirmed salivary gland carcinoma.
  2. Patients with advanced or recurrent salivary gland cancer who are not candidates for curative surgery or radiotherapy.
  3. Measurable disease per the RECIST criteria. For disease occurring in previously irradiated field, there must be confirmed progression prior to the date registration and more than three months after completion of radiotherapy
  4. ECOG performance status 0-2.
  5. Prior CNS involvement by tumor is permissible if previously treated and clinically stable for two weeks after completion of treatment.
  6. At least a 2-week recovery from prior therapy toxicity.
  7. Provision of written informed consent.
  8. Childbearing potential either terminated by surgery, radiation, or menopause, or attenuated by use of an approved contraceptive method (IUD, birth control pills, or barrier device) during and for 3 months after completion of trial therapy.

Exclusion Criteria:

  1. Known severe hypersensitivity to or any of the excipients of this product.
  2. Other coexisting malignancies or malignancies diagnosed within the last 5 years, with the exception of basal cell carcinoma, squamous cell carcinoma of the skin, or cervical cancer in situ.
  3. Concomitant use of phenytoin, carbamazepine, rifampicin, phenobarbital, or St John's Wort or CYP3A4 (e.g. itraconazole, ketoconazole)
  4. Treatment with a investigational drug within 28 days before Day 1 of trial treatment.
  5. Any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer therapy (except alopecia)
  6. Incomplete healing from previous surgery.
  7. Serum creatinine level greater than CTC grade 2.
  8. Women who are pregnant or breast feeding.
  9. Prior or other EGFR inhibiting agents.
  10. Serum bilirubin greater than 1.25 times the upper limit of reference range (ULRR).
  11. Any evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease).
  12. Alanine amino transferase (ALT) or aspartate amino transferase (AST) greater than 2.5 times the ULRR if no demonstrable liver metastases or greater than 5 times the ULRR in the presence of liver metastases.
  13. Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the trial.
  14. Uncontrolled seizure disorder, active neurological disease, or greater than Grade 2 neuropathy.
  15. Keratoconjunctivitis sicca or incompletely treated eye infection.
  16. Abnormal marrow function as defined as absolute neutrophil count <1,500/ul or platelets <100,000/ul.
  17. Second primary malignancy (except in situ carcinoma of the cervix or adequately treated nonmelanomatous carcinoma of the skin or other malignancy treated at least 3 years previously with no evidence of recurrence; prior low grade [Gleason score less than 6] localized prostate cancer is allowed).
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00509002

Locations
United States, Texas
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
AstraZeneca
Investigators
Principal Investigator: George Blumenschein, MD M.D. Anderson Cancer Center
  More Information

Additional Information:
UT MD Anderson Cancer Center website  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT00509002     History of Changes
Other Study ID Numbers: 2004-0089
Study First Received: July 26, 2007
Last Updated: September 22, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by M.D. Anderson Cancer Center:
Salivary Gland Cancer
Iressa
ZD1839

Additional relevant MeSH terms:
Salivary Gland Neoplasms
Mouth Neoplasms
Head and Neck Neoplasms
Neoplasms by Site
Neoplasms
Mouth Diseases
Stomatognathic Diseases
Salivary Gland Diseases
 Gefitinib
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on February 12, 2012



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services